托莫西汀治疗合并抽动秽语综合征儿童的注意力缺陷多动障碍
Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
作者信息
Spencer Thomas J, Sallee F Randy, Gilbert Donald L, Dunn David W, McCracken James T, Coffey Barbara J, Budman Cathy L, Ricardi Randall K, Leonard Henrietta L, Allen Albert J, Milton Denai R, Feldman Peter D, Kelsey Douglas K, Geller Daniel A, Linder Steven L, Lewis Donald W, Winner Paul K, Kurlan Roger M, Mintz Mark
机构信息
Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114-2696, USA.
出版信息
J Atten Disord. 2008 Jan;11(4):470-81. doi: 10.1177/1087054707306109. Epub 2007 Oct 12.
OBJECTIVE
This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS).
METHOD
Subjects (7-17 years old) with ADHD (Diagnostic and Statistical Manual of Mental Disorders, DSM-IV) and TS were randomly assigned to double-blind treatment with placebo (n = 56) or atomoxetine (0.5-1.5 mg/kg/day, n = 61) for approximately 18 weeks.
RESULTS
Atomoxetine subjects showed significantly greater improvement on ADHD symptom measures. Treatment was also associated with significantly greater reduction of tic severity on two of three measures. Significant increases were seen in mean pulse rate and rates of treatment-emergent nausea, decreased appetite, and decreased body weight. No other clinically relevant treatment differences were observed in any other vital sign, adverse event, laboratory parameter, or electrocardiographic measure.
CONCLUSION
Atomoxetine is efficacious for treatment of ADHD and its use appears well tolerated in ADHD patients with comorbid TS.
目的
本研究探讨托莫西汀治疗患有抽动秽语综合征（TS）的注意缺陷多动障碍（ADHD）患者时，抽动症状及ADHD严重程度的变化。
方法
将符合《精神疾病诊断与统计手册》第四版（DSM-IV）标准的7至17岁ADHD合并TS患者随机分为两组，分别接受为期约18周的双盲安慰剂治疗（n = 56）或托莫西汀治疗（0.5 - 1.5 mg/kg/天，n = 61）。
结果
托莫西汀治疗组在ADHD症状指标上改善更为显著。在三项评估指标中的两项上，该治疗还与抽动严重程度的显著降低相关。平均脉搏率、治疗中出现恶心、食欲减退及体重下降的发生率均显著增加。在其他生命体征、不良事件、实验室参数或心电图指标方面，未观察到其他具有临床意义的治疗差异。
结论
托莫西汀对ADHD治疗有效，且在合并TS的ADHD患者中耐受性良好。
Zotero 插件